ImmunityBio Q2 revenue up 60%, surpassing market estimates, on strong sales of ANKTIVA
Overview
ImmunityBio Q2 2025 revenue rises 60% to $26.4 mln, beating analyst expectations
Company's revenue growth driven by ANKTIVA sales in BCG-unresponsive NMIBC
ImmunityBio ends Q2 with $153.7 mln in cash, plus $80 mln equity financing
Result Drivers
ANKTIVA SALES - 60% revenue increase in Q2 2025 driven by strong sales of ANKTIVA in BCG-unresponsive NMIBC
UNIT GROWTH - 246% increase in ANKTIVA unit sales volume in 1H 2025 compared to 2H 2024 post J-code approval
FINANCIAL POSITION - $80 mln equity financing in July 2025 strengthens cash reserves, enhancing financial stability
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $26.42 mln | $22.80 mln (5 Analysts) |
Q2 Net Income |
| -$92.57 mln |
|
Q2 Operating Income |
| -$71.28 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Immunitybio Inc is $8.00, about 69.9% above its August 4 closing price of $2.41
Press Release: ID:nBw9ZXscka
